Evidence map›Paper›PMID 34013111›Full record

ArticleKidney international reports2021

Rare Collagenous Heterozygote Variants in Children With IgA Nephropathy.

Alexandra Cambier, Thomas Robert, Julien Hogan, Marion Rabant, Michel Peuchmaur, Olivia Boyer, Tim Ulinski, Renato C Monteiro, Laurent Mesnard

Open access · goldAbstract read
In one paragraph

Article in Kidney international reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Guideline
  2. Article
  3. Article
  4. Article
  5. Review
  6. Explaining Alport syndrome-lessons from the adult nephrology clinic.Journal of rare diseases (Berlin, Germany) · 2024
    Review
  7. Article
  8. The 2019 and 2021 International Workshops on Alport Syndrome.European journal of human genetics : EJHG · 2022
    Article
  9. Identification ofFrontiers in genetics · 2022
    Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 2 countries.

Alexandra CambierService de néphrologie pédiatrique, APHP, Hôpital Universitaire Robert-Debré, Paris, France.
Thomas RobertCentre de néphrologie et transplantation rénale, APHM, Hôpital Universitaire de la Conception, Marseille, France.
Julien HoganService de néphrologie pédiatrique, APHP, Hôpital Universitaire Robert-Debré, Paris, France.
Marion RabantService de Pathologie, Hôpital Universitaire Hôpital Necker, APHP, Paris, France.
Michel PeuchmaurService de Pathologie, Hôpital Universitaire Robert Debré APHP, Paris et Université Diderot, Paris, France.
Olivia BoyerService de néphrologie pédiatrique, APHP, Hôpital Universitaire Necker, Paris, France.
Tim UlinskiService de néphrologie pédiatrique, APHP, Hôpital Trousseau, Paris, France.
Renato C MonteiroUniversité de Paris, Paris, France; INSERM U1149; CNRS ERL8252; Centre de recherche sur l'inflammation; Inflamex Laboratory of Excellence, Paris, France.
Laurent MesnardInserm UMR_S1155, Paris, France.
Centre National de la Recherche Scientifique · FRHôpital Necker-Enfants Malades · FRInserm · FRAssistance Publique – Hôpitaux de Paris · FRDélégation Paris 7 · FRSorbonne Université · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionChildhood IgA nephropathy (cIgAN) is a primary glomerulonephritis clinically characterized by microscopic hematuria and proteinuria, the presence of which may potentially overlap with Alport syndrome. Interestingly, earlier studies suggested that familial IgAN could be linked to the chromosome 2q36 region, also the coding region for collagen type 4 alpha 3/4 (COL4A3/A4).

methodsTo investigate a possible relationship or phenocopy between Alport syndrome and cIgAN, COL4A3, COL4A4, and COL4A5 exons were sequenced in 36 cIgAN patients. Clinical data and treatment were collected retrospectively. COL4A3/A4/A5 variants were classified according to American College of Medical Genetics and the Association for Molecular Pathology (ACMG/AMP) guidelines.

resultsFour of 36 cIgAN patients were affected by ACMG class 4/5 COL4A3 heterozygous variants (COL4A3-cIgAN). We found no COL4A4 or COL4A5 variant. Despite having rare and deleterious COL4A3 variants, 3 of 4 COL4A3-cIgAN children developed clinical and biologic features of active IgAN rather than Alport syndrome. Response to intensive immunosuppressive treatment was favorable, leading to a reduction of endocapillary and extracapillary proliferation lesions. High levels of immune immunoglobulin G and A (IgG/IgA) complexes, reduction of proteinuria, and gradual stabilization of estimated glomerular filtration rate (eGFR) argued against Alport syndrome. Nevertheless, COL4A3-cIgAN patients seemed predisposed to a more serious IgAN presentation compared with the non‒COL4A3-cIgAN group, with more glomerulosclerosis and a lower eGFR over time. One of the 4 patients underwent kidney transplant with subsequent IgAN recurrence.

conclusionsPredisposition factors for developing serious cIgAN flare-up should be considered for cIgAN with COL4A3 pathologic heterozygous variants. COL4A3 variants, usually responsible for Alport syndrome in adults, should not automatically exclude an immunosuppressive regimen in cIgAN. Moreover, evidence of an ACMG class 4/5 COL4A3 variant in early-stage cIgAN could be a helpful tool for stratifying severity of cIgAN beyond the Oxford classification.

Indexed as

Alport syndromechildrenCOL4A3 variantsIgA nephropathyimmunosuppressive treatmentOxford classification

Identifiers

PMID34013111
PMCPMC8116726
OpenAlexW3135032231

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.